Navigation Links
CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Date:3/11/2009

taneous bleeding and bone, joint or tissue hemorrhage. Diminished concentrations of fibrinogen, also called Factor I (one), limit the body's ability to form a clot. Certain fibrinogen levels usually indicate normal blood clotting ability. To determine fibrinogen levels and confirm a diagnosis, blood coagulation testing is needed.

RiaSTAP is a purified fibrinogen concentrate that undergoes virus inactivation and removal for safety assurance. There have been more than 1 million units sold worldwide (marketed outside the U.S. under the trade name Haemocomplettan(R) P). CSL Behring is studying RiaSTAP in an ongoing post-marketing commitment study to further demonstrate safety and hemostatic efficacy.

About RiaSTAP

RiaSTAP is a purified fibrinogen concentrate indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. RiaSTAP is not indicated for dysfibrinogenemia. RiaSTAP is contraindicated in individuals who have had severe immediate hypersensitivity reactions, including anaphylaxis to RiaSTAP or its components.

Physicians should monitor patients for early signs of allergic or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. Thrombotic events have been reported in patients receiving RiaSTAP. Physicians should weigh the benefits of administration versus the risks of thrombosis.

RiaSTAP is made from pooled human plasma. Products made from human plasma may contain infectious agents (e.g., viruses and theoretically the Creutzfeldt-Jakob disease agent (CJD) that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by a process demonstrated to inactivate
'/>"/>

SOURCE CSL Behring
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
2. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
3. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
4. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
5. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
6. deCODE Receives California Clinical Laboratory License
7. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
8. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
9. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications
10. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
11. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Roche,s Bloodhound technology is on the ... hematology testing, according to Kalorama Information.  The healthcare ... its Bloodhound digital cell imaging technology –as newly ... hematology analyzer – is notable as a play ... leader CellaVision, but also compete more broadly in ...
(Date:7/2/2015)... 26, 2015 Research and Markets( ... D Market by Analog, Application, End-User & by Region - ... offering. This market is projected to reach about ... in different applications and rising opportunities in countries such as ... Italy , and Brazil ...
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... Oriental Bioengineering, Inc. (NYSE: AOB ) ("the ... health through the development, manufacture and commercialization of a ... products, today announced that it plans to release third ... after the market closes.   The Company ...
... 1, 2010 The U.S. Food and Drug ... Friday to treat patients with subependymal giant cell ... rare genetic disorder. This approval was for treatments ... surgery. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:American Oriental Bioengineering to Announce Third Quarter 2010 Financial Results on November 9, 2010 2FDA Approves New Indication for Afinitor 2FDA Approves New Indication for Afinitor 3
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first ... and athletic trainers. Their significant popularity has inspired four new, fun shades including: ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com recently ... passion for social fitness. Built to function as a lifestyle community, Active Bunch allows ... the opportunity to network, meet, and participate in discussions or group events. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... company , announced today that it has reached an agreement to acquire ... CleanItSupply.com the largest distributor of Rubbermaid Commercial Products on the web today. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Octo Consulting Group, (Octo), a ... government, has announced they are among nine contractors awarded the U.S. Securities and ... contract not to exceed $250 million. , To achieve the goals of ...
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
Breaking Medicine News(10 mins):Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3
... Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that Richard Van der Jagt, M.D. of ... the 2009 Pan Pacific Lymphoma Conference on Monday, June 22, 2009. The conference will be ... Hawaii. , , , ... 2009 Pan Pacific Lymphoma Conference, ...
... , , , President Obama Calls For Health ... 15 The American Medical Association warmly welcomed U.S. ... Like the president, the AMA is committed to health reform this ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) , ...
... MBA, FACPE, Ameritox,s Senior Vice President and Chief Medical Officer, ... for the American College of Physician Executives (ACPE), a national ... , Dr. Leider became an ACPE member 20 years ... College for 13 years teaching courses on improving the quality ...
... 16, 2009 at 9:00 a.m. Eastern Time , , ... ALXA ) announced today that it has exercised ... Allegro. The purchase of Symphony Allegro, which is subject ... 2009. , , Alexza and Symphony Capital Partners, LP ...
... June 15 Citing evidence that even a very low level ... the Council of State and Territorial Epidemiologists (CSTE) is recommending a ... adults. In a vote at the CSTE annual conference in Buffalo, ... 10 ug/dl or more in adults as "elevated" -- the same ...
... 15, 2009 (BRONX, NY) In a study ... researchers from Albert Einstein College of Medicine of Yeshiva ... HIV-positive individuals are most likely to develop deadly fungal ... of meningitis affects more than 900,000 HIV-infected people globallymost ...
Cached Medicine News:Health News:President Obama Receives Warm Welcome from AMA Physicians 2Health News:Ameritox(R) CMO Elected Chairman of the American College of Physician Executives Board 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 3Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 4Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 5Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 6Health News:CSTE Leads Effort to Improve Blood Lead Reporting 2Health News:CSTE Leads Effort to Improve Blood Lead Reporting 3Health News:Predicting fatal fungal infections 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
... Clinicians are demanding smaller, higher performing ... clinical and operational challenges. The new ... powerful architecture for superb High Definition ... and ease-of-use; and a versatile suite ...
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea...
... InfinixTM CF-i/SP brings revolutionary flexibility to ... enables operators to move the C-arm ... to obtain the optimal angle for ... features an 8-inch cardiac flat panel ...
Medicine Products: